These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 19414372)

  • 1. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.
    Fang Y; Elahi A; Denley RC; Rao PH; Brennan MF; Jhanwar SC
    Anticancer Res; 2009 Apr; 29(4):1255-62. PubMed ID: 19414372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of copy number variation and gene expression in neurofibromatosis type-1-associated malignant peripheral nerve sheath tumours.
    Thomas LE; Winston J; Rad E; Mort M; Dodd KM; Tee AR; McDyer F; Moore S; Cooper DN; Upadhyaya M
    Hum Genomics; 2015 Feb; 9(1):3. PubMed ID: 25884485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.
    Mitchell DK; Burgess B; White EE; Smith AE; Sierra Potchanant EA; Mang H; Hickey BE; Lu Q; Qian S; Bessler W; Li X; Jiang L; Brewster K; Temm C; Horvai A; Albright EA; Fishel ML; Pratilas CA; Angus SP; Clapp DW; Rhodes SD
    Clin Cancer Res; 2024 Mar; 30(5):1038-1053. PubMed ID: 38127282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 modulates kinase inhibitor resistance and lineage plasticity in NF1-related MPNSTs.
    Grit JL; McGee LE; Tovar EA; Essenburg CJ; Wolfrum E; Beddows I; Williams K; Sheridan RTC; Schipper JL; Adams M; Arumugam M; Vander Woude T; Gurunathan S; Field JM; Wulfkuhle J; Petricoin EF; Graveel CR; Steensma MR
    Oncogene; 2024 May; 43(19):1411-1430. PubMed ID: 38480916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.
    Borcherding DC; Amin NV; He K; Zhang X; Lyu Y; Dehner C; Bhatia H; Gothra A; Daud L; Ruminski P; Pratilas CA; Pollard K; Sundby T; Widemann BC; Hirbe AC
    Clin Cancer Res; 2023 Apr; 29(8):1592-1604. PubMed ID: 36799629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.
    Suppiah S; Mansouri S; Mamatjan Y; Liu JC; Bhunia MM; Patil V; Rath P; Mehani B; Heir P; Bunda S; Velez-Reyes GL; Singh O; Ijad N; Pirouzmand N; Dalcourt T; Meng Y; Karimi S; Wei Q; Nassiri F; Pugh TJ; Bader GD; Aldape KD; Largaespada DA; Zadeh G
    Nat Commun; 2023 May; 14(1):2696. PubMed ID: 37164978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.
    Longo JF; Brosius SN; Black L; Worley SH; Wilson RC; Roth KA; Carroll SL
    Cell Commun Signal; 2019 Jul; 17(1):74. PubMed ID: 31291965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.
    Shurell E; Vergara-Lluri ME; Li Y; Crompton JG; Singh A; Bernthal N; Wu H; Eilber FC; Dry SM
    Oncotarget; 2016 Nov; 7(45):72860-72867. PubMed ID: 27655679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated risk for MPNST in NF1 microdeletion patients.
    De Raedt T; Brems H; Wolkenstein P; Vidaud D; Pilotti S; Perrone F; Mautner V; Frahm S; Sciot R; Legius E
    Am J Hum Genet; 2003 May; 72(5):1288-92. PubMed ID: 12660952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.
    Somatilaka BN; Madana L; Sadek A; Chen Z; Chandrasekaran S; McKay RM; Le LQ
    J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38502231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decorin suppresses stemness and migration potential of malignant peripheral nerve sheath tumor through inhibiting epidermal growth factor receptor signaling.
    Jia X; Chen L; Yu C
    Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167181. PubMed ID: 38653361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.
    Wojtkowiak JW; Fouad F; LaLonde DT; Kleinman MD; Gibbs RA; Reiners JJ; Borch RF; Mattingly RR
    J Pharmacol Exp Ther; 2008 Jul; 326(1):1-11. PubMed ID: 18367665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitotic recombination of chromosome arm 17q as a cause of loss of heterozygosity of NF1 in neurofibromatosis type 1-associated glomus tumors.
    Stewart DR; Pemov A; Van Loo P; Beert E; Brems H; Sciot R; Claes K; Pak E; Dutra A; Lee CC; Legius E
    Genes Chromosomes Cancer; 2012 May; 51(5):429-37. PubMed ID: 22250039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.
    Larsson AT; Bhatia H; Calizo A; Pollard K; Zhang X; Conniff E; Tibbitts JF; Rono E; Cummins K; Osum SH; Williams KB; Crampton AL; Jubenville T; Schefer D; Yang K; Lyu Y; Pino JC; Bade J; Gross JM; Lisok A; Dehner CA; Chrisinger JSA; He K; Gosline SJC; Pratilas CA; Largaespada DA; Wood DK; Hirbe AC
    Neuro Oncol; 2023 Nov; 25(11):2044-2057. PubMed ID: 37246765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.
    Godec A; Jayasinghe R; Chrisinger JSA; Prudner B; Ball T; Wang Y; Srihari D; Kaushal M; Dietz H; Zhang X; Pekmezci M; Dahiya S; Tao Y; Luo J; Van Tine BA; Ding L; Gutmann DH; Hirbe AC
    Neurooncol Adv; 2020 Jul; 2(Suppl 1):i75-i84. PubMed ID: 32642734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular targets for NF1-associated malignant peripheral nerve sheath tumor.
    Binobaid L; Masternak MM
    Rep Pract Oncol Radiother; 2020; 25(4):556-561. PubMed ID: 32494228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.
    Dodd RD; Mito JK; Eward WC; Chitalia R; Sachdeva M; Ma Y; Barretina J; Dodd L; Kirsch DG
    Mol Cancer Ther; 2013 Sep; 12(9):1906-17. PubMed ID: 23858101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner.
    Turbyville TJ; G├╝rsel DB; Tuskan RG; Walrath JC; Lipschultz CA; Lockett SJ; Wiemer DF; Beutler JA; Reilly KM
    Mol Cancer Ther; 2010 May; 9(5):1234-43. PubMed ID: 20442305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary Approach to Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
    Hirbe AC; Dehner CA; Dombi E; Eulo V; Gross AM; Sundby T; Lazar AJ; Widemann BC
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432242. PubMed ID: 38710002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models.
    Jenkins DP; Turner-Ivey B; Fromm Longo J; Carroll SL
    J Vis Exp; 2024 May; (207):. PubMed ID: 38829133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.